| Literature DB >> 34886459 |
Yehuda Weizman1, Oren Tirosh1, Jeanie Beh2, Franz Konstantin Fuss3, Sonja Pedell2.
Abstract
The ability of people living with dementia to walk independently is a key contributor to their overall well-being and autonomy. For this reason, understanding the relationship between dementia and gait is significant. With rapidly emerging developments in technology, wearable devices offer a portable and affordable alternative for healthcare experts to objectively estimate kinematic parameters with great accuracy. This systematic review aims to provide an updated overview and explore the opportunities in the current research on wearable sensors for gait analysis in adults over 60 living with dementia. A systematic search was conducted in the following scientific databases: PubMed, Cochrane Library, and IEEE Xplore. The targeted search identified 1992 articles that were potentially eligible for inclusion, but, following title, abstract, and full-text review, only 6 articles were deemed to meet the inclusion criteria. Most studies performed adequately on measures of reporting, in and out of a laboratory environment, and found that sensor-derived data are successful in their respective objectives and goals. Nevertheless, we believe that additional studies utilizing standardized protocols should be conducted in the future to explore the impact and usefulness of wearable devices in gait-related characteristics such as fall prognosis and early diagnosis in people living with dementia.Entities:
Keywords: dementia; falls; gait; gait assessment; inertial measurement unit; sensors; wearable devices
Mesh:
Year: 2021 PMID: 34886459 PMCID: PMC8656771 DOI: 10.3390/ijerph182312735
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Study characteristics.
| Author [ref’] | Country | Aim | Population Type | Selection Criteria of Dementia Participants | Participants Characteristics |
|---|---|---|---|---|---|
| Ardle et al., 2020 | UK | To assess whether a single accelerometer-based wearable could differentiate | (1) Alzheimer’s disease dementia (ADD), | Inclusion: (1) over 60 years old, (2) able to walk for two | N: 32 (ADD); Gender: M/F: 15/17; |
| Gietzelt et al., 2014 | Germany | To make a fall prognosis in a cohort of older people with dementia in short-term (2 month), mid-term (4 month), and long-term (8 month) | adults with dementia | Inclusion: (1) over 65 years, (2) can do TUG > 15 s, (3) Mini Mental State Examination (MMSE) 524 points, (4) recurrent falls, (5) signed written informed consent by the subjects’ legal guardians. | N: 40 |
| Williams et al., 2018 | UK | To explore relationships between the instrumented Timed Up and Go test (iTUG) and the following risk factors for falls: cognitive functioning, fear of falling (FoF), and quality of life (QoL) in people with dementia. | adults with dementia | Inclusion: (1) living at home, (2) have a diagnosis of a dementia, | N: 83 |
| Schwenk et al., 2014 | Germany | To explore the validity of sensor derived physical activity (PA) parameters for predicting future falls in people with dementia (24 h). To compare sensor-based fall risk assessment with conventional fall risk measures. | adults with dementia (fallers and non-fallers) | Inclusion: (1) over 65 years old, (2) cognitive impairment (Mini-Mental State Examination), a dementia diagnosis was confirmed according to international standards, 3) informed consent, approval by the legal guardian (if appointed), and (4) no uncontrolled or terminal neurological, cardiovascular, metabolic, or psychiatric disorder. | N: 28 (fallers); Gender: M/F: 6/22; Age: 82.0 ± 7.1; |
| Ijmker et al., 2012 | Netherlands | To investigate differences in the relationship between | (1) dementia group | Inclusion: (1) diagnosis of (pre)senile dementia (Alzheimer’s disease or FrontoTemporal dementia), (2) an MMSE-score 16. | N: 15 (dementia); Gender: M/F: 13/2; |
| Ardle et al., 2021 | UK | To investigate how different environments (lab, real world) impact gait. | (1) dementia Lewy bodies, | Inclusion: (1) aged over 60 years, (2) able to walk for two minutes, as ascertained by self-report. | N: 28 (DLB); Gender: M/F: 22/6; |
Study parameters and outcome measures.
| Author [Ref’] | Sensor Type | Location on the Body | Calculated Gait Parameter | Gait Assessment Protocol | Environment | Main Findings |
|---|---|---|---|---|---|---|
| Ardle et al., 2020 | IMU: AX3, Axivity; sampling at 100 Hz | above the fifth lumbar vertebra (L5) | (1) pace, (2) variability, (3) rhythm, (4) asymmetry, (5) postural control | 6 × 10 m; comfortable paste | controlled environment | - the wearable device differentiated dementia disease subtypes ( |
| Gietzelt et al., 2014 | IMUs: SHIMMER; and MMA7260QT; sampling rate was not reported | trunk | (1) anterior-posterior acceleration, (2) average kinetic energy, (3) compensation movements, (4) step frequency, (5) number of dominant peaks | (1) TUG, (2) 4 × one-week sensor-based measurement (every 2 months) | everyday life (nursing home) | - evaluation of the models showed a rate of correctly classified gait episodes of 88.4% (short-term), 74.8% (midterm), and 88.5% (long-term) monitoring. |
| Williams et al., 2018 | IMU: THETAmetrix; sampling at 30 Hz | middle of the lower back | linear accelerations and rotational velocities | instrumented Timed Up and Go Test (iTUG) | controlled environment | - cognition was related to duration of walking sub-phases and total time to complete iTUG (r = 0.25–0.28) suggesting that gait speed was related to cognition. |
| Schwenk et al., 2014 | IMU: Physilog, BioAGM; sampling at 40 Hz | chest | (1) walking during 24 h, (2) walking bout average duration, (3) longest walking bout duration, (4) walking bout duration variability, (5) standing during 24 h, (6) standing bout average duration, (7) sitting during 24 h, (8) sitting bout average duration, and (9) lying during 24 h | (1) Timed Up and Go Test, (2) 5-Chair Stand, (3) 24-h period, (4) follow up after 3 months (no sensor) | real world (everyday life) | - fallers and non-fallers did not differ on any conventional assessment ( |
| Ijmker et al., 2012 | IMU: DynaPort1 MiniMod, McRoberts BV; sampling at 100 Hz | trunk | anterior-posterior and medio-lateral accelerations time-series | 3 min at comfortable pace (10 m long course); (1) once under single and (2) once under dual task condition | controlled environment | - patients with dementia exhibited a significantly ( |
| Ardle et al., 2021 | IMU: AX3, Axivity; sampling at 20 Hz | (1) above the fifth lumbar vertebra (L5); (2) 7 days—lower backs | (1) pace, (2) variability, (3) rhythm, (4) asymmetry, (5) postural control | (1) controlled environment (lab): 6 × 10 m at comfortable pace; (2) 7 days—real world (everyday life) | (1) controlled environment; (2) real world (everyday life) | - in the lab, DLB group showed greater step length variability ( |
Quality assessment questions.
| Question | Ardle et al., 2020 | Gietzelt et al., 2014 | Williams et al., 2018 | Schwenk et al., 2014 | Ijmker et al., 2012 | Ardle et al., 2021 |
|---|---|---|---|---|---|---|
| Q1. Is the hypothesis/aim/objective of the study clearly described? | Y | Y | Y | Y | Y | Y |
| Q2. Are the main outcomes clearly described in the Introduction or Methods? | Y | Y | Y | Y | Y | Y |
| Q3. Are the characteristics of the participants clearly described (including age, sex, and status as healthy/injured/pathological)? | Y | Y | Y | N | Y | Y |
| Q4. Are the inclusion/exclusion criteria described and appropriate? | Y | Y | Y | N | Y | Y |
| Q5. Are the main findings of the study clearly described? | Y | Y | Y | Y | Y | Y |
| Q6. Are estimates of the random variability in the data for the main outcomes provided? | Y | N | Y | Y | Y | Y |
| Q7. Have actual probability values been reported for the main outcomes? | Y | N | Y | Y | Y | Y |
| Q8. Are the participants representative of the entire population from which | Y | Y | Y | Y | Y | Y |
| Q9. Are the setting and conditions typical for the population represented by the participants? | Y | Y | Y | Y | Y | Y |
| Q10. Are the statistical tests used to assess the main outcomes appropriate? | Y | Y | Y | Y | Y | Y |
| Q11. Are the main outcome measures used accurate (valid and reliable)? | Y | Y | Y | Y | Y | Y |
| Q12. Is a sample size justification, power description, or variance and effect estimates provided? | N | N | N | N | N | N |
Note: Y = Yes, N = No.
Figure 1Strategy of literature review process.